Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TSR-042 (dostarlimab) in advanced clear cell sarcoma
2016-004368-21Phase 2Terminated
- Sponsor
- Italian Sarcoma Group
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in clear cell sarcoma (CCS), sponsored by Italian Sarcoma Group. Primary endpoint: Objective response rate (RECIST v1.1). Started Oct 2020; status: terminated.
02
Drugs
dostarlimab
03
Conditions
clear cell sarcoma (CCS)
Beyond the preview
Go deeper on 2016-004368-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004368-21.